Enalapril: Pharmacokinetic/dynamic inferences for comparative developmental toxicity

Reproductive Toxicology

Volumn 15, Issue 5, 2001, Pages 467-478

  Tabacova, Sonia A ^a   Kimmel, Carole A ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

ACE inhibitor; Animal human comparisons; Developmental toxicity; Enalapril; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRIL MALEATE; ENALAPRILAT;

ADULT; ANIMAL; ANIMAL MODEL; COMPARATIVE STUDY; DEVELOPMENTAL DISORDER; DRUG EFFECT; DRUG STRUCTURE; FEMALE; FETUS DEVELOPMENT; FETUS DISEASE; HUMAN; KIDNEY DEVELOPMENT; MACACA; MATERNAL HYPERTENSION; NONHUMAN; OSSIFICATION; PHARMACODYNAMICS; PREGNANCY; PRENATAL DEVELOPMENT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPECIES DIFFERENCE;

ADULT; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; EMBRYONIC AND FETAL DEVELOPMENT; ENALAPRIL; FEMALE; HUMANS; MACACA MULATTA; MODELS, ANIMAL; PREGNANCY; SPECIES SPECIFICITY;

EID: 0034822751     PISSN: 08906238     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0890-6238(01)00161-7     Document Type: Review

References (95)

1. ACE inhibitor fetopathy and hypocalvaria: The kidney-skull connection
2. A new class of angiotensin-converting enzyme inhibitors
3. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors
4. Bioavailability of enalapril maleate
5. The physiological disposition and metabolism of enalapril maleate in laboratory animals
6. Effect of N-[(s)-1-carboxyl-3-phenylpropyl]-L-Ala-L-Pro and its ethyl ester (MK 421) on angiotensin converting enzyme in vitro and angiotensin pressor responses in vivo
7. Enalapril maleate and a lysine analogue (MK-521): Disposition in man
8. The excretion of enalapril and enalaprilat in human breast milk
9. Comment
10. Metabolic fate of the new angiotensin-converting enzyme inhibitor Imidapril in animals. 4th communication: Placental transfer and secretion into milk in rats
11. Placental passage of angiotensin-converting enzyme inhibitors
12. Pharmacokinetic and fetal cardiovascular effects of enalaprilat administration to maternal rhesus macaque
13. The effect of enalapril (MK-421), an angiotensin converting enzyme inhibitor, on the conscious pregnant ewe and her fetus
14. Teratogen update: Angiotensin-converting enzyme inhibitors
15. Fertility and perinatal/postnatal studies in rats with the angiotensin-converting enzyme inhibitor, quinapril
16. Enalapril for pregnancy-induced hypertension: Acute renal failure in a neonate
17. Enalapril: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure
18. An overview of the influence of ACE inhibitors on fetal-placental circulation and perinatal development
19. Renal and adrenal responses to converting-enzyme inhibition in fetal and newborn life
20. Angiotensin converting enzyme inhibitors in pregnancy
21. Transcription of testicular angiotensin-converting enzyme (ACE) is initiated within the 12th intron of the somatic ACE gene
22. Structure of the angiotensin 1-converting enzyme gene: Two alternative promoters correspond to evolutionary steps of a duplicated gene
23. The mRNAs encoding the two angiotensin-converting isozymes are transcribed from the same gene by a tissue specific choice of alternative transcription initiation sites
24. Structure and regulated expression of angiotensin-converting enzyme and the receptor for angiotensin II
25. Angiotensin 1 converting enzyme
26. Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enzyme activity and response to angiotensin I
27. Antihypertensive effect of the new oral angiotensin converting enzyme inhibitor MK-421
28. Effects of enalapril, a new converting enzyme inhibitor, in hypertension
29. Angiotensin-converting enzyme inhibitors, an embryopathic class of drugs with unique properties: Information for clinical teratology counselors
30. A radioimmunoassay for aldosterone in human peripheral plasma including a comparison of alternate techniques
31. Intrarenal control of electrolyte excretion by angiotensin II
32. Control of glomerular filtration rate by the renin-angiotensin system
33. Effect of captopril on uterine blood flow and prostaglandin E synthesis in the pregnant rabbit
34. Uterine blood flow and uterine renin secretion
35. Plasma renin, renin substrate, angiotensin II, and aldosterone in hypertensive disease of pregnancy
36. The effect of prostaglandin inhibition on uterine blood flow
37. Prostacyclin in pregnancy
38. Prostacyclin produced by the pregnant uterus in the dog may act as a circulating vasodepressor substance
39. Renin-angiotensin system in placenta
40. Regional blood flow and vascular resistance of the fetus in uterine action of vasoactive drugs
41. The effect of angiotensin II intravenous infusion of plasma renin activity and prostaglandins A, E, and F levels in the uterine vein of the pregnant monkey
42. The effect of angiotensin II and indomethacin on uterine artery blood flow in pregnant monkeys
43. A study of angiotensin II pressor response throughout primigravid pregnancy
44. Plasma renin activity during ovine pregnancy
45. Control of vascular responsiveness during pregnancy
46. Increased platelet angiotensin II receptor number in pregnancy-induced hypertension
47. The dynamics of vasopressin release and blood volume regulation during fetal hemorrhage in the lamb fetus
48. Ontogeny of the renin-angiotensin system in the fetal and newborn lamb
49. Distribution of angiotensin II receptors and renin in the mouse fetus
50. Characterization and distribution of angiotensin II receptors in the primate fetus
51. Angiotensin-II receptor subtypes in fetal tissues of the rat: Autoradiography, guanine nucleotide sensitivity, and association with phospholipide hydrolysis
52. Identification of angiotensin II receptor subtypes
53. Expression of AT2 receptors in the developing rat fetus
54. Distribution of type I angiotensin II receptor subtype messenger RNAs in the rat fetus
55. The renin-angiotensin system in the perinatal period in rats
56. Plasma renin activity responses to graded decreases in renal perfusion pressure in fetal and newborn lambs
57. Distribution of renin mRNA and its protein in the developing kidney
58. Developmental changes in renin gene expression in ovine kidney cortex
59. Fetal expression of the angiotensinogen gene
60. Ontogeny of somatic angiotensin-converting enzyme
61. Comparison of the adrenal and renal responses to angiotensin II in fetal lambs and adult sheep
62. Development of angiotensin-converting enzyme in fetal rat lungs
63. Distribution and development of angiotensin converting enzyme in fetal and newborn rabbit
64. Captopril administration to the pregnant guinea pig inhibits fetal angiotensin converting enzyme activity
65. Pulmonary fate of vasoactive peptides in fetal, newborn, and adult sheep
66. Adverse effects of drugs on the immature kidney
67. Population genetics of the angiotensin-converting enzyme in Chinese
68. Familial resemblance of plasma angiotensin I-converting enzyme level: The Nancy study
69. Distribution of plasma angiotensin I-converting enzyme in healthy men: Relationship to environmental and hormonal parameters
70. An insertion deletion polymorphism in angiotensin I converting enzyme gene accounting for half the variance of serum enzyme levels
71. Relationship between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications
72. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin 1-converting enzyme (ACE) gene controls plasma ACE activity
73. Effect of ACE inhibition on the fetal kidney: Decreased renal blood flow
74. Studies on the circulation of the previable human fetus
75. Effect of carbon dioxide elevation on renal blood flow in the fetal lamb in utero
76. Can captopril cause fetal and neonatal renal failure?
77. Angiotensin-converting enzyme inhibitors in pregnancy may result in neonatal renal failure
78. Fetal exposure to lisinopril: Neonatal manifestations and management
79. The effect of captopril upon mother and fetus in chronically cannulated ewe and in the pregnant rabbit
80. Angiotensin-converting enzyme activity and its modulation by oxygen tension in the guinea pig fetal-placental unit
81. Maternotoxicity and fetotoxicity of an angiotensin-converting enzyme inhibitor, enalapril, in rabbits
82. Fetotoxicity of angiotensin-converting enzyme inhibition in primate pregnancy: A prospective, placebo-controlled study in baboons (Papio hamadryas)
83. Cardiorespiratory effects of calcium channel-blocker tocolysis in pregnant rhesus monkeys
84. Effects of calcium entry blocker (nicardipine) tocolysis in rhesus macaques: Fetal plasma concentrations and cardiorespiratory changes
85. Renin and angiotensin
86. Pathophysiology of fetal renal disease
87. Cell and molecular studies of renin secretion
88. Functional toxicity in the developing heart, lung, and kidney
89. Renin-angiotensin system in neonatal rats: Induction of a renal abnormality in response to ACE inhibition or angiotensin-II antagonism
90. Angiotensin-converting enzyme inhibitor fetopathy
91. Effects of angiotensin II on bone cells in vitro
92. Angiotensin II stimulates the proliferation of osteoblast-rich populations of cells from rat calvariae